Xencor, Inc.

John O Richards

John R Desjarlais

Gregory Alan Lazar

Sher Bahadur Karki

Matthew J Bernett

Seung Yup Chu

Eugene Alexander Zhukovsky

Erik Weiking Pong

Umesh Muchhal

Duc-Hanh Thi Nguyen

Gregory L Moore

David F Carmichael

Umesh S Muchhal

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

Optimized antibodies that target CD19

The present invention describes antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an Fcg&#x3b3;R or alters effector function as compared to the parent antibody. Also disclosed are methods of using the antibodies of the invention.

The present invention relates to Fc variants with optimized Fc receptor binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc receptor binding properties, and methods for using Fc variants with optimized Fc receptor binding properties.

Modified FC molecules

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one modification relative to a parent antibody that alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

Optimized antibodies that target HM1.24

Antibodies that target CD19, wherein the antibodies comprise at least one modification relative to a parent antibody, wherein the modification alters affinity to an FcyR or alters effector function as compared to the parent antibody, and methods of using the antibodies.

The present disclosure describes antibodies that target HM1.24. In various aspects, the antibodies have specific CDR, variable, or full length sequences, have modifications with the parent antibody, or include at least one one modification relative to a parent antibody that alters affinity to an Fc&#x3b3;R or alters effector function as compared to the parent antibody. Nucleic acids encoding the antibodies and methods of using the antibodies are also disclosed.

Growing community of inventors

Duarte, CA, United States of America

John O Richards